Item 3.
Legal Proceedings.
105
Item 4.
Mine Safety Disclosures.
106
Part II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
107
Item 6.
[Reserved].
107
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
108
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk.
119
Item 8.
Financial Statements and Supplementary Data.
120
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
149
Item 9A.
Controls and Procedures.
149
Item 9B.
Other Information.
149
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
149
Part III
Item 10.
Directors, Executive Officers and Corporate Governance.
151
Item 11.
Executive Compensation.
156
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
164
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
167
Item 14.
Principal Accounting Fees and Services.
170
Part IV
Item 15.
Exhibits, Financial Statement Schedules.
171
Item 16.
Form 10-K Summary.
173
Signatures
174
2
Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K (“10-K”), contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. In some cases, forward-looking statements may be identified by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” “strive,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this 10-K are based upon information available to our management as of the date of this 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this 10-K include, but are not limited to, statements about:
•
the initiation, timing, progress and results (preliminary, interim or final) of our preclinical studies and clinical trials, and our research and development programs including ORX750, ORX142, ORX489 and other orexin agonist molecules, other LockBody candidates, and the LockBody technology platform; 
•
our ability to execute our research and clinical development plans and our expectations on and the timing thereof;
•
our expectations and ability to advance our pipeline and product candidates into, and successfully complete, clinical trials;
•
our ability to identify screen, recruit and maintain a sufficient number of, or any, subjects in our existing and anticipated studies or clinical trials including the ongoing Phase 1 first-in-human, clinical trial and Phase 2 clinical trial of ORX750 and other orexin agonist molecules, and any other LockBody candidates;
•
our ability to differentiate ORX750, ORX142, ORX489, other orexin agonist molecules and other LockBody candidates from other treatment options; 
•
the development and therapeutic potential of ORX750, ORX142, ORX489 and other orexin agonist molecules, LockBody candidates, and the LockBody technology platform;
•
our expectations relating to the ongoing Phase 1 first-in-human, clinical trial, the Phase 2 clinical trial of ORX750, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and our ability to successfully conduct our clinical development of ORX750;
•
the safety and tolerability profile of our product candidates; 
•
our reliance on the success of our product candidates and our pipeline programs; 
•
our ability to discover and develop transformational medicines for patients including identifying and advancing additional product candidates into clinical development; 
•
our ability to become the partner of choice to attract founder-subject matter experts with high conviction programs; 
•
the timing or likelihood of regulatory filings and approvals; 
•
the impact of inflation on increasing costs of labor, research, manufacturing and clinical trial expenses;
•
the impact of the Russia-Ukraine war, the Middle East conflict(s) and tensions in U.S.-China relations on our business and operations; 
•
the commercialization of our product candidates, if approved; 
•
our ability to develop sales and marketing capabilities; 
•
the pricing, coverage and reimbursement of our product candidates, if approved; 
•
the implementation of our business model, strategic plans for our business, product candidates and technology;
•
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; 
•
our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; 
•
cost associated with prosecuting and maintaining our intellectual property and with defending intellectual property infringement, product liability and other claims; 
•
legal and regulatory developments in the United States, the European Union, the United Kingdom and other jurisdictions; 
•
estimates of our expenses, future revenues, capital requirements and our needs for additional financing; 
•
the potential benefits of strategic collaboration agreements and our ability to negotiate and enter into strategic arrangements; 
•
our ability to identify collaboration opportunities and to establish and maintain collaborations;
3
Table of Contents

•
our ability to judiciously manage and allocate our cash;
•
our expectations on our anticipated cash runway;
•
our ability to obtain additional funding; 
•
our ability to fulfill our obligations under the Loan and Security Agreement with Oxford Finance LLC (as Collateral Agent and Lender), Oxford Finance Credit Fund II LP (as a Lender) and Oxford Finance Credit Fund III LP (as a Lender) (collectively “Oxford Finance”);
•
the rate and degree of market acceptance of any approved products; 
•
developments relating to our competitors and our industry, including competing therapies and our ability to respond to such developments; 
•
our ability to effectively manage our anticipated growth; 
•
our ability to attract and retain qualified employees and key personnel; 
•
our expectations regarding the period during which we qualify as a smaller reporting company and as an emerging growth company under the JOBS Act;  
•
statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; 
•
our expected use of proceeds of 
our capital 
raises; 
•
the future trading price of the ADSs and impact of securities analysts’ reports on these prices; and 
•
other risks and uncertainties, including those listed under the caption “Risk Factors.”
You should refer to the section titled “